What are the main new MedTech platforms Johnson & Johnson introduced this quarter?

Johnson & Johnson introduced CARTOSOUND SONATA (AI-powered imaging and mapping for cardiac electrophysiology), received FDA authorization for THERMOCOOL SMARTTOUCH SF (a dual-energy ablation system combining pulsed field and radiofrequency energy), launched OTTAVA (a table-integrated robotic surgical system), and announced plans for MONARCH for Urology subject to regulatory approval.

When is CARTOSOUND SONATA expected to be adopted in the U.S. market?

Management expects adoption of CARTOSOUND SONATA to continue during the second half of 2026.

How does the investigational erdafitinib device differ from INLEXZO?

The erdafitinib device is designed to provide three months of sustained medicine delivery, compared with the three-week delivery period associated with INLEXZO.

AI in HealthcareAI Business & IndustryRoboticsTop Companies' AI MovesTop Companies AIJul 16, 2026Jul 17, 2026, 06:31 JST3 min read

J&J Q2 Sales Rise 5.6%; Unveils AI Imaging and Robotic Surgery Platforms

Send on LINE

Key takeaway

Johnson & Johnson reported second-quarter 2026 sales of $25.3 billion（約4兆円） with 5.6% operational growth, driven by launches of AI-powered imaging and robotic surgical platforms.
The company is building a connected MedTech ecosystem that links devices, software, and clinical data to improve surgical workflows and clinical efficiency, positioning itself as a major player in surgical robotics by the end of the decade.

3 Key Points

What happened
Johnson & Johnson reported second-quarter 2026 worldwide sales of $25.3 billion（約4兆円）, up 5.6% operationally, with adjusted net earnings rising 5.7% to $7.1 billion（約1.1兆円）. The company introduced several connected MedTech platforms: CARTOSOUND SONATA (AI-powered cardiac imaging), THERMOCOOL SMARTTOUCH SF (dual-energy ablation system with FDA authorization), OTTAVA (table-integrated robotic surgery system), and announced plans for MONARCH for Urology.
Why it matters
Johnson & Johnson is building an integrated ecosystem linking medical devices, software, and clinical data to strengthen digital capabilities and clinical efficiency across its portfolio. CEO Joaquin Duato described OTTAVA as "one of the most significant MedTech innovations we will bring to market this decade," signaling the company's commitment to become a major participant in surgical robotics—a competitive area where differentiation through connected platforms and data-driven insights can support sustained growth.
What to watch
Management expects CARTOSOUND SONATA adoption to continue in the United States during the second half of 2026 as it responds to competitive pressure in pulsed field ablation. The company believes OTTAVA and MONARCH could contribute meaningfully to MedTech growth by the end of the decade. An investigational erdafitinib device for bladder cancer, designed to deliver medicine over three months (compared with INLEXZO's three-week delivery), is also under development and could extend the device-enabled approach to oncology care.

Ask the AI about this article →

Summaries like this, in your inbox every morning.

Get news like this every morning — free

Context & Analysis

Johnson & Johnson's second-quarter results reflect solid operational momentum—sales growth of 5.6% with Innovative Medicine delivering 6.8% growth—but the company's strategic emphasis on connected MedTech platforms signals a deeper shift in how it plans to compete. The introduction of CARTOSOUND SONATA, THERMOCOOL SMARTTOUCH SF, OTTAVA, and the planned MONARCH for Urology are not isolated product launches; they represent a deliberate strategy to create an integrated digital ecosystem that links hardware, software, and clinical data. CEO Duato's characterization of OTTAVA as "one of the most significant MedTech innovations we will bring to market this decade" underscores management's confidence that surgical robotics—combined with data-driven insights from an open digital platform—can drive substantial revenue growth.

The competitive context matters: CARTOSOUND SONATA is explicitly positioned to respond to competitive pressure in pulsed field ablation, while THERMOCOOL SMARTTOUCH SF's dual-energy capability allows physicians to choose the right tool for each procedure, potentially reducing reliance on separate systems. The device-enabled oncology approach—exemplified by the three-month erdafitinib device versus the three-week INLEXZO—extends this logic beyond surgery into medical delivery, suggesting J&J believes connected, data-informed platforms can address fragmentation across the healthcare system and create durable competitive advantages.

FAQ

What are the main new MedTech platforms Johnson & Johnson introduced this quarter?: Johnson & Johnson introduced CARTOSOUND SONATA (AI-powered imaging and mapping for cardiac electrophysiology), received FDA authorization for THERMOCOOL SMARTTOUCH SF (a dual-energy ablation system combining pulsed field and radiofrequency energy), launched OTTAVA (a table-integrated robotic surgical system), and announced plans for MONARCH for Urology subject to regulatory approval.
When is CARTOSOUND SONATA expected to be adopted in the U.S. market?: Management expects adoption of CARTOSOUND SONATA to continue during the second half of 2026.
How does the investigational erdafitinib device differ from INLEXZO?: The erdafitinib device is designed to provide three months of sustained medicine delivery, compared with the three-week delivery period associated with INLEXZO.